Literature DB >> 15755964

Optimizing endocrine therapy for breast cancer.

Eric P Winer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15755964     DOI： 10.1200/JCO.2005.01.005

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  Genomic index of sensitivity to endocrine therapy for breast cancer.

Authors:  W Fraser Symmans; Christos Hatzis; Christos Sotiriou; Fabrice Andre; Florentia Peintinger; Peter Regitnig; Guenter Daxenbichler; Christine Desmedt; Julien Domont; Christian Marth; Suzette Delaloge; Thomas Bauernhofer; Vicente Valero; Daniel J Booser; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

Review 2.  Cancer Treatment-Induced Bone Loss: Role of Denosumab in Non-Metastatic Breast Cancer.

Authors:  Boman Dhabhar
Journal:  Breast Cancer (Dove Med Press)       Date:  2022-07-14

3.  A new small molecule inhibitor of estrogen receptor alpha binding to estrogen response elements blocks estrogen-dependent growth of cancer cells.

Authors:  Chengjian Mao; Nicole M Patterson; Milu T Cherian; Irene O Aninye; Chen Zhang; Jamie Bonéy Montoya; Jingwei Cheng; Karson S Putt; Paul J Hergenrother; Elizabeth M Wilson; Ann M Nardulli; Steven K Nordeen; David J Shapiro
Journal:  J Biol Chem       Date:  2008-03-12       Impact factor: 5.157

4.  Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study.

Authors:  Dong Hoe Koo; Cheol-Young Park; Eun Sook Lee; Jungsil Ro; Sang Woo Oh
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

5.  Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.

Authors:  Denis Collins; Wolfgang Jacob; Juan Miguel Cejalvo; Maurizio Ceppi; Ian James; Max Hasmann; John Crown; Andrés Cervantes; Martin Weisser; Birgit Bossenmaier
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

6.  New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus.

Authors:  Elisavet Paplomata; Ruth O'Regan
Journal:  Ther Clin Risk Manag       Date:  2013-01-14       Impact factor: 2.423

7.  Is tamoxifen associated with an increased risk for thromboembolic complications in patients undergoing microvascular breast reconstruction?

Authors:  Andreas Jokuszies; Christine Radtke; Christopher Betzler; Ludwik Branski; Robert Krämer; Peter M Vogt
Journal:  Ger Med Sci       Date:  2013-02-18

Review 8.  The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.

Authors:  C J Fabian
Journal:  Int J Clin Pract       Date:  2007-09-24       Impact factor: 2.503
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.